Cost-effectiveness of treating latent tuberculous infection: A step towards elimination?

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 12, 2013, Pages 1515-

  Diel, Roland ^a   Loddenkemper, Robert ^b   Sotgiu, Giovanni ^c   Migliori, G B ^d  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b German Central Committee Against Tuberculosis   (Germany)

^c UNIVERSITY OF SASSARI   (Italy)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAPENTINE;

COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG COST; DRUG SELF ADMINISTRATION; EDITORIAL; HUMAN; LATENT TUBERCULOSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SHORT COURSE THERAPY;

ANTITUBERCULAR AGENTS; DRUG COSTS; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; RIFAMPIN;

EID: 84888087948     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0706     Document Type: Editorial

References (6)

1. Diel R, Loddenkemper R, Zellweger J P, et al. Old ideas to innovate TB control: preventive treatment to achieve elimination. Eur Respir J 2013 Feb 8. [Epub ahead of print]
2. Clancy L, Rieder H L, Enarson D A, Spinaci S. Tuberculosis elimination in the countries of Europe and other industrialised countries. Eur Respir J 1991; 4: 1288-1295.
3. Shepardson D, Marks S M, Chesson H, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis 2013; 17: 1531-1537.
4. Sterling T R, Villarino M E, Borisov A S, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
5. Grosse S D. Assessing cost-effectiveness in healthcare: history of the $50 000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 165-178. (Pubitemid 351959547)
6. World Health Organization. Report of the 13th meeting of the WHO Strategic and Technical Advisory Group for Tuberculosis (STAG-TB), 11-12 June 2013. WHO/HTM/TB/2013.09. Geneva, Switzerland: WHO, 2013.